Scholarlink

Introduction <p>Respiratory syncytial virus (RSV) is the leading cause of respiratory infections and hospitalization among infants and a major burden on pediatric emergency department (EDs). Nirsevimab has recently been introduced for universal use in all infants entering their first RSV season. However, real-world data on its public health impact are still limited, particularly regarding attendances at pediatric ED.</p> Methods <p>We conducted a retrospective, observational, pre–post intervention study at the Meyer Children’s Hospital (Tuscany, Italy). The 2024–25 RSV season, when nirsevimab was firstly implemented, was compared with the three preceding seasons. ED attendances, hospitalization, and pediatric intensive care unit (PICU) admissions for lower respiratory tract infections (LRTIs) of any etiology were analyzed.</p> Results <p>During the 2024–25 season, overall ED attendances for LRTIs, regardless of etiology, decreased by 67.3%. Hospital admissions for LRTIs dropped by 64.7%, and PICU admissions by 86.2%. RSV-confirmed LRTIs declined by 96.5%.</p> Conclusions <p>Universal nirsevimab prophylaxis markedly reduced the burden of respiratory infections in eligible infants, leading to a significant reduction in the use of healthcare resources, including ED visits, hospitalization, and PICU admissions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre–Post Observational Study in Tuscany, Italy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Francesco Nieddu,
  • Marta Verzieri,
  • Marina Vignoli,
  • Valeria Astorino,
  • Silvia Boscia,
  • Laura Pisano,
  • Silvia Ricci,
  • Lorenzo Lodi,
  • Valentina Guarnieri,
  • Francesca Di Berardino,
  • Francesca Figlioli,
  • Stefano Masi,
  • Giuseppe Indolfi,
  • Chiara Azzari,
  • Maria Moriondo

摘要

Introduction

Respiratory syncytial virus (RSV) is the leading cause of respiratory infections and hospitalization among infants and a major burden on pediatric emergency department (EDs). Nirsevimab has recently been introduced for universal use in all infants entering their first RSV season. However, real-world data on its public health impact are still limited, particularly regarding attendances at pediatric ED.

Methods

We conducted a retrospective, observational, pre–post intervention study at the Meyer Children’s Hospital (Tuscany, Italy). The 2024–25 RSV season, when nirsevimab was firstly implemented, was compared with the three preceding seasons. ED attendances, hospitalization, and pediatric intensive care unit (PICU) admissions for lower respiratory tract infections (LRTIs) of any etiology were analyzed.

Results

During the 2024–25 season, overall ED attendances for LRTIs, regardless of etiology, decreased by 67.3%. Hospital admissions for LRTIs dropped by 64.7%, and PICU admissions by 86.2%. RSV-confirmed LRTIs declined by 96.5%.

Conclusions

Universal nirsevimab prophylaxis markedly reduced the burden of respiratory infections in eligible infants, leading to a significant reduction in the use of healthcare resources, including ED visits, hospitalization, and PICU admissions.